Global /South Korea /Healthcare /Drug Manufacturers - General /060590

CTCBIO Inc.

060590

• KRX: 060590 • Delayed

3,910KRW 1.3%

2.59 USD

As of 19 June 2026, CTCBIO Inc. has a market cap of $61.29M USD, ranking #29112 globally and #1586 in South Korea. It ranks #2638 in the Healthcare sector, and #938 in the Drug Manufacturers - General industry.

Global Rank

29112

Country Rank

1586

Sector Rank

2638

Industry Rank

938

Key Stats

Market Cap

$61.29MUSD

93.48B KRW

Enterprise Value

$78.72MUSD

118.83B KRW

Revenue (TTM)

$81.14MUSD

123.77B KRW

EBITDA (TTM)

$8.47MUSD

12.78B KRW

Net Income (TTM)

$2.12MUSD

3.24B KRW

EBITDA Margin

10%

Profit Margin

2.6%

PE Ratio

28.5

PS Ratio

0.8

PB Ratio

1.2

EV/EBITDA

9.3

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Mingoo Lee open_in_new

Employees

248

Founded

1993

Website

ctcbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
1.3%	0.8%	-0.9%	-13%	-28%	-15%	-43%	-60%	-46%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	060590 (주)씨티씨바이오 ISIN: KR7060590007 Shares Out.: Shares Outstanding: 23.909M¹ Shares Float: 13.514M² TV: TradingView: KRX: 060590 SA: Stock Analysis: KRX: 060590 YF: Yahoo Finance: 060590.KS GF: Google Finance: KRX: 060590 BA: Barron's: 060590 MS: Morningstar: XKRX: 060590	3,910 KRW	TV: TradingView: KRX: 060590 SA: Stock Analysis: KRX: 060590 YF: Yahoo Finance: 060590.KS GF: Google Finance: KRX: 060590 BA: Barron's: 060590 MS: Morningstar: XKRX: 060590

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About CTCBIO Inc.

CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergic rhinitis and antihistamine, neuropsychiarty, intestinal disorders, X-ray, diabetes, anti-inflammatory and arthritis, and harmones, as well as CTC covid-19 IgM/IgG combo test, a quick antibody test kit on covid-19. In addition, the company offers coating base/plasticizer/pore former, diluting agents, bonding agents, disintegrating agents, lubricants, solubilizer/biopharma, topicals, APIs, and food/health functional foods, as well as animal drugs, physiological activators, functional enhancers, and disinfectants. CTCBIO Inc. was founded in 1993 and is headquartered in Hwaseong-si, South Korea.

Similar Companies

Industry: Drug Manufacturers - General (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Epis Holdings Co., Ltd. KRX: 0126Z0	$9.12B 13.91T KRW 15K%	-	South Korea
Sam Chun Dang Pharm. Co., Ltd. KRX: 000250	$6.75B 10.3T KRW 11K%	1958.1	South Korea
SK Biopharmaceuticals Co., Ltd. KRX: 326030	$5.23B 7.97T KRW 8K%	29.9	South Korea
ABL Bio Inc. KRX: 298380	$4.95B 7.55T KRW 8K%	-	South Korea
Yuhan Corp. KRX: 000100	$4.54B 6.92T KRW 7K%	35.9	South Korea
LigaChem Biosciences Inc. KRX: 141080	$4.43B 6.76T KRW 7K%	-	South Korea

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 1M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 893K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 588K%	97.4	United States
Roche Holding AG SIX: RO	$321.45B 256.25B CHF 524K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$287.52B 215.59B GBP 469K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.59B 218.9B CHF 448K%	20.5	Switzerland

chevron_leftBack